Start here: the honest default
No treatment is approved for long COVID. This page is a strategy that combines a symptom approach with ordinary cardiac caution, and the two halves rest on different strengths of evidence, which is worth keeping separate in your mind.
Most post-COVID chest pain and palpitations are not coming from a damaged heart. They are more often the autonomic nervous system misfiring, which is reassuring in one sense and still very much worth addressing.
Part one: treat the substrate
The first move is to treat the overlapping POTS and dysautonomia that often generate chest pain and palpitations, since settling the autonomic problem tends to settle the symptoms it produces.
That substrate approach is graded low and thin, based on symptom relief rather than controlled trials. It is reasonable and often helpful, but its evidence is modest, and saying so plainly is part of the honesty here.
lowthin evidencesymptom relief
Part two: keep watching the heart
The second move is cardiac surveillance, and it rests on far stronger ground. Population data show that COVID raises the longer-term risk of genuine cardiovascular events, even in people who were not hospitalized.1 That is a reason to stay watchful, not to panic.
The two parts answer different questions. Treating the substrate is about easing what you feel; surveillance is about not missing the rarer, real cardiac problem.
What the surveillance side involves
Cardiac surveillance does not mean living in a state of constant alarm. It means keeping up sensible follow-up, taking new or changing symptoms seriously, and not assuming that because most post-COVID chest symptoms turn out to be autonomic, every one of them must be. The aim is measured watchfulness calibrated to your own risk with a clinician, not blanket testing or blanket reassurance.
The justification is population data: COVID raises the longer-term risk of genuine cardiovascular events even in people who were never hospitalized.1 That is a real signal, and it is the stronger-evidence half of this two-part strategy. It does not mean a heart attack is likely; it means the background risk is modestly raised enough that staying watchful, rather than dismissive, is the reasonable stance.
Reading risk without panic
The skill this page asks for is holding two true things at once. Most of your chest pain and palpitations are probably autonomic and not dangerous, and the underlying population risk of real cardiac events is modestly raised. Neither cancels the other, and the trap is collapsing into one of them, either dismissing every symptom as nerves or treating every flutter as catastrophe.
The way through is neither dismissal nor dread. Treat the autonomic driver to settle the day-to-day symptoms, keep up the recommended follow-up, and treat any new, severe, or changing chest pain as a prompt to seek care promptly rather than something to ride out alone. That combination, calm management of the common cause plus alertness to the uncommon one, is the whole strategy in a sentence.
Keeping the two halves separate
It helps to keep the two strands of this strategy clearly apart in your mind, because they rest on very different strengths of evidence. Treating the overlapping POTS and dysautonomia that generate chest pain and palpitations is graded low and thin, based on symptom relief rather than controlled trials. Keeping watch on the heart rests on far stronger population-level evidence.
A strong reason to monitor the heart is not a strong treatment, and a weak treatment signal for the autonomic substrate is not a reason to skip monitoring. If your chest symptoms have been worked up and the heart looks structurally fine, treating the autonomic driver is a reasonable way to settle them, with the honest caveat that the evidence for that approach is modest, while the surveillance half is the part to take seriously and keep up.
What to weigh
Keep the strands separate. A strong reason to monitor the heart is not a strong treatment, and a weak treatment signal for the autonomic substrate is not a reason to skip monitoring. New, severe, or changing chest pain always warrants prompt assessment rather than self-management.
What we don't know
Honest about the edges of the evidence. These are open questions, not settled answers.
- How much chest pain and palpitations are autonomic versus cardiac in any given person.
- Which surveillance approach best catches the events that matter without overtesting.
- Whether treating the autonomic substrate lowers cardiac risk or only eases symptoms.
- How long the elevated cardiovascular risk persists after infection.
- Which patients warrant closer cardiac follow-up than others.
- Whether earlier autonomic treatment changes the longer-term cardiac picture.
What this means for you
If your chest symptoms have been worked up and your heart looks structurally fine, treating the autonomic driver is a reasonable way to settle them, with the honest caveat that the evidence for that approach is modest.
At the same time, take the surveillance half seriously: keep up recommended follow-up, and treat any new, severe, or changing chest pain as a reason to seek care promptly. The goal is to calm the common autonomic cause while staying alert to the uncommon cardiac one.
References
Each reference links to the source on PubMed, PMC, or the publisher.